AIDS Therapies

Passive Immunization Yields High Levels of Anti-HIV Antibody

Published in Blood Weekly, September 8th, 1997

AIDS patients who receive passive immunization with hyperimmune anti-HIV immunoglobulin achieve serum titers of anti-HIV antibodies similar to those that neutralize the virus in laboratory cultures.

The finding comes from a clinical trial of HIVIG, the commercial HIV hyperimmune serum preparation manufactured by North American Biologicals, Boca Raton, Florida.

"This study indicates that high titers of anti-p24 antibody can be maintained with a monthly administration schedule of HIVIG and that short-term safety is acceptable," wrote University of Minnesota researcher Courtney V. Fletcher and colleagues. "Comparisons to evaluate the therapeutic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry